Referencing Guidelines

Researchers accessing data from the WHO TB-IPD platform are required to acknowledge the source appropriately. When publishing research findings that utilize data from the TB-IPD platform, please include citations for the TB-IPD editorial available on the Ingenta Connect website. The TB-IPD platform’s webpage at TB-IPD platform|UCL-University College London, and the relevant publications from our data contributors. A comprehensive list of these contributions will be provided to data analysts in the form of a spreadsheet to ensure all sources are accurately credited.   

We provide two options for standard acknowledgment paragraphs, depending on the allowable word count:

Full option

This work uses data obtained through the WHO TB Treatment Individual Patient Data Platform (TB-IPD), a collaborative initiative to support the generation of reliable evidence on the treatment of TB to inform future TB treatment guidelines. It is supported by the WHO Global TB Programme and maintained by UCL. The current TB-IPD includes previous work collected at McGill University, as published in Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients | PLOS Medicine and Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis - The Lancet, and at Sydney University, as published in Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis | Clinical Infectious Diseases | Oxford Academic. We acknowledge the contributors and their individual patients for their invaluable contributions.

Extended acknowledgement for paediatric and pregnancy data use

This work uses data obtained through the WHO TB Treatment Individual Patient Data Platform (TB-IPD), a collaborative initiative to support the generation of reliable evidence on the treatment of TB to inform future TB treatment guidelines. It is supported by the WHO Global TB Programme and maintained by UCL. The current TB-IPD includes previous work collected at McGill University, as published in Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients | PLOS Medicine and Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis - The Lancet, and at Sydney University, as published in Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis | Clinical Infectious Diseases | Oxford Academic. Paediatric and Pregnancy data were collected at Stellenbosch University, as published in Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis | PLOS Medicine. We acknowledge the contributors and their individual patients for their invaluable contributions.

Short Option

This work uses data obtained through the WHO TB treatment individual patient data platform (TB-IPD), a collaborative initiative led by the World Health Organization (WHO), Global TB Programme and University College London (UCL).

To reference the IPD we suggest the following:

Recommended citation (TB-IPD):

• Goodall RL, et al. A publicly accessible global data repository–the WHO TB-IPD platform. IJTLD OPEN. 2024 Apr 1;1(4):151-3.
• World Health Organization Tuberculosis treatment individual patient data platform. University College London. Available at: .https://www.ucl.ac.uk/global-health/research/z-research/tb-ipd-platform
• Ahuja SD, et al., the Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med. 2012; 9:e1001300.
• Ahmad N, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. The Lancet. 2018 Sep 8;392(10150):821-34.
• Hasan T, et al. The safety and tolerability of linezolid in novel short-course regimens containing bedaquiline, pretomanid, and linezolid to treat rifampicin-resistant tuberculosis: an individual patient data meta-analysis. Clinical Infectious Diseases. 2024 Mar 15;78(3):730-41.
• Harausz EP, et al. Treatment and outcomes in children with multidrug-resistant tuberculosis: a systematic review and individual patient data meta-analysis. PLoS medicine. 2018 Jul 11;15(7):e1002591.